| Filed |
Name |
|
Company |
Pur. £ |
Cur. £ |
P/L % |
MPV* |
|
Feb '17
|
Lord Arbuthnot of Edrom
|
|
Neuro-bio / NMS:NBIX |
£43.24
|
£127.78
|
195.51%
|
£206,859.38
|
|
Apr '16
|
Baroness Greenfield
|
|
Neuro-bio / NMS:NBIX |
£46.13
|
£127.78
|
177.00%
|
£193,899.84
|
|
Mar '24
|
Lord Moynihan of Chelsea
|
|
Journey Medical / NCM:DERM |
£3.74
|
£7.25
|
93.85%
|
£135,695.19**
|
|
Jul '23
|
Lord Sassoon
|
|
Haleon / LSE:HLN.L |
£336.10
|
£373.00
|
10.98%
|
£77,685.21
|
|
Mar '25
|
Lord Fink
|
|
Zoetis / NYQ:ZTS |
£162.82
|
£115.46
|
-29.09%
|
£49,638.86
|
|
Apr '21
|
Baroness Deech
|
|
Zoetis / NYQ:ZTS |
£168.10
|
£115.46
|
-31.31%
|
£48,079.71
|
|
Mar '17
|
Lord Lloyd-Webber
|
|
Hikma Pharmaceuticals / LSE:HIK.L |
£2,026.00
|
£1,209.00
|
-40.33%
|
£41,771.96
|
|
Mar '24
|
Lord Moynihan of Chelsea
|
|
Evotec / NMS:EVO |
£7.13
|
£3.41
|
-52.17%
|
£33,478.26**
|
* Minimum Potential Value based on £70,000.00 invested at time of declaration.
** Interest ceased/exited on filed date.